Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the presentation of data for its lead drug candidate, ANG1005, a novel paclitaxel-peptide drug conjugate, at the American Society of Clinical Oncology 50th Annual Meeting in Chicago, IL.

31 May 2014

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Angiochem announced today that the Food & Drug Association (FDA) has granted both orphan drug and fast track designation to ANG1005 a novel paclitaxel-peptide drug conjugate leveraging the low density lipoprotein receptor-related protein 1 (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer, for the treatment of glioblastoma multiforme (GBM).

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in HER2+ breast cancer patients.

31 May 2014

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas.

28 May 2014

Researchers use computer simulations to identify drugs most likely to kill cancer cells

Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have used computer simulations of cancer cells - cancer avatars - to identify drugs most likely to kill cancer cells isolated from patients' brain tumors.

22 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study released ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Ill.

15 May 2014

SapC-DOPS technology: New way to image glioblastoma multiforme tumors

Just because you can't see something doesn't mean it's not there. Brain tumors are an extremely serious example of this and are not only difficult to treat-both adult and pediatric patients have a five-year survival rate of only 30 percent-but also have even been difficult to image, which could provide important information for deciding next steps in the treatment process.

15 May 2014

Research team identifies specific genes that may lead to improved survival of glioblastoma

A Henry Ford Hospital research team has identified specific genes that may lead to improved survival of glioblastoma, the most common and deadly form of cancerous brain tumor.

13 May 2014

Biochemists identify protein that can slow down growth of brain tumors in mice

Much like using dimmer switches to brighten or darken rooms, biochemists have identified a protein that can be used to slow down or speed up the growth of brain tumors in mice.

12 May 2014

Study reveals how ovarian cancer metabolism changes between early, late stages

A Rice University-led analysis of the metabolic profiles of hundreds of ovarian tumors has revealed a new test to determine whether ovarian cancer cells have the potential to metastasize, or spread to other parts of the body. The study also suggests how ovarian cancer treatments can be tailored based on the metabolic profile of a particular tumor.

6 May 2014

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

Novogen Limited, an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.

5 May 2014

UCSD neurosurgeons study MRI-guided biopsy approach to diagnose patients with brain cancer

Neurosurgeons at UC San Diego Heath System have, for the first time, combined real-time magnetic resonance imaging (MRI) technology with novel non-invasive cellular mapping techniques to develop a new biopsy approach that increases the accuracy of diagnosis for patients with brain cancer.

2 May 2014

Human fat: A Trojan horse to fight brain cancer?

Johns Hopkins researchers say they have successfully used stem cells derived from human body fat to deliver biological treatments directly to the brains of mice with the most common and aggressive form of brain tumor, significantly extending their lives.

1 May 2014

Researchers create tiny, biodegradable nanoparticles that carry DNA to brain cancer cells

Working together, Johns Hopkins biomedical engineers and neurosurgeons report that they have created tiny, biodegradable “nanoparticles” able to carry DNA to brain cancer cells in mice.

30 Apr 2014

Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

A class of drugs developed to treat immune-related conditions and cancer - including one currently in clinical trials for glioblastoma and other tumors - eliminates neural inflammation associated with dementia-linked diseases and brain injuries, according to UC Irvine researchers.

17 Apr 2014

TGen honors two philanthropists for supporting TGen's research on brain, colon and prostate cancer

The Translational Genomics Research Institute (TGen) recently honored two significant Arizona philanthropists at their annual Founders Dinner for their support of TGen's research into brain, colon and prostate cancer. The event took place March 28 in Scottsdale.

17 Apr 2014

Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Skatchewan is a vast prairie province in the middle of Canada. It's home to hockey great Gordie Howe and the world's first curling museum. But Canadians know it for another reason: it's the birthplace of the country's single-payer health-care system.

11 Apr 2014

Glioblastoma News and Research

Further Reading

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

FDA grants Angiochem’s ANG1005 fast track and orphan drug designation for treatment of glioblastoma multiforme

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Angiochem commences ANG1005 Phase 2 clinical study in HER2+ breast cancer patients with brain metastases

CytRx announces Phase 2b clinical trial results of aldoxorubicin in subjects with metastatic STS

Researchers use computer simulations to identify drugs most likely to kill cancer cells

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Phase I study reveals abemaciclib drug shows evidence of single-agent activity in NSCLC patients

SapC-DOPS technology: New way to image glioblastoma multiforme tumors

Research team identifies specific genes that may lead to improved survival of glioblastoma

Biochemists identify protein that can slow down growth of brain tumors in mice

Study reveals how ovarian cancer metabolism changes between early, late stages

Novogen partners with Genea Biocells to accelerate testing for neurodegenerative diseases

UCSD neurosurgeons study MRI-guided biopsy approach to diagnose patients with brain cancer

Human fat: A Trojan horse to fight brain cancer?

Researchers create tiny, biodegradable nanoparticles that carry DNA to brain cancer cells

Researchers develop class of drugs to lessen impact of Alzheimer's, Parkinson's

TGen honors two philanthropists for supporting TGen's research on brain, colon and prostate cancer

Longer looks: Vermont's single payer system; Nevada's cancer cluster; the toll of dementia on a family

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News